These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36423169)

  • 1. Molnupiravir: From Hope to Epic Fail?
    Focosi D
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
    Yip AJW; Low ZY; Chow VTK; Lal SK
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pandemic COVID-19, an update of current status and new therapeutic strategies.
    Vitiello A; La Porta R; Trama U; Ferrara F; Zovi A; Auti AM; Di Domenico M; Boccellino M
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Oct; 395(10):1159-1165. PubMed ID: 35779085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
    Khiali S; Khani E; B Rouy S; Entezari-Maleki T
    Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro.
    Liu D; Leung KY; Lam HY; Zhang R; Fan Y; Xie X; Chan KH; Hung IF
    Virus Res; 2024 Jul; 345():199371. PubMed ID: 38621598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.
    Abdelnabi R; Foo CS; De Jonghe S; Maes P; Weynand B; Neyts J
    J Infect Dis; 2021 Sep; 224(5):749-753. PubMed ID: 34244768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molnupiravir in COVID-19: A Scoping Review.
    Kaore S; Atal S
    Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Siniavin AE; Gushchin VA; Shastina NS; Darnotuk ES; Luyksaar SI; Russu LI; Inshakova AM; Shidlovskaya EV; Vasina DV; Kuznetsova NA; Savina DM; Zorkov ID; Dolzhikova IV; Sheremet AB; Logunov DY; Zigangirova NA; Gintsburg AL
    Antiviral Res; 2024 May; 225():105871. PubMed ID: 38555022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of molnupiravir and interferon for the treatment of SARS-CoV-2 in golden Syrian hamster.
    Liu D; Leung KY; Zhang R; Lam HY; Fan Y; Xie X; Chan KH; Hung IF
    J Med Virol; 2024 Sep; 96(9):e29901. PubMed ID: 39210614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molnupiravir: an antiviral drug against COVID-19.
    Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
    Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
    Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
    Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
    Sanderson T; Hisner R; Donovan-Banfield I; Hartman H; Løchen A; Peacock TP; Ruis C
    Nature; 2023 Nov; 623(7987):594-600. PubMed ID: 37748513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the Omicron variant development.
    Vitiello A; Ferrara F; Auti AM; Di Domenico M; Boccellino M
    J Intern Med; 2022 Jul; 292(1):81-90. PubMed ID: 35289434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.